Wegovy® Lawsuit

The weight loss drug Wegovy® has been linked to severe health complications, including vision loss from non-arteritic anterior ischemic optic neuropathy (NAION) and stomach paralysis.

At Sokolove Law, we’ve recovered over $1.6 Billion for clients injured by dangerous drugs or medical devices. Call (800) 995-1212 now to see if our Wegovy lawyers may be able to help your family.

Get a Free Wegovy Case Review

Semaglutide in Wegovy Linked to Severe Risks

Wegovy is an injectable weight loss medication by Novo Nordisk that contains semaglutide. By slowing the digestion process, users may feel fuller longer. However, growing research suggests that semaglutide may carry serious risks, including vision loss.

Some patients who developed serious side effects like non-arteritic anterior ischemic optic neuropathy (NAION) are filing lawsuits against Novo Nordisk, alleging the company knew or should've known about these risks and failed to warn them.

Find out more about Wegovy lawsuits: 

  • Multiple studies have linked semaglutide, the active ingredient in Wegovy, to an increased risk of vision loss from NAION.
  • Despite this, Wegovy’s warning label has not yet been updated to reflect the risk of NAION.
  • Affected patients may be able to file a Wegovy NAION lawsuit to pursue compensation for medical bills, lost wages, pain and suffering, and other damages related to their vision loss.
  • To date, over 200 lawsuits linking GLP-1 medications to NAION have been consolidated in a multidistrict litigation (MDL No. 3163) in the Eastern District of Pennsylvania, including claims involving Wegovy.

At Sokolove Law, we have more than 45 years of experience fighting for justice on behalf of our clients and holding negligent companies accountable for the harm they’ve caused. See if we can help you file a Wegovy NAION lawsuit now.

Get Help Paying for Treatment

If you developed health issues like NAION after using Wegovy, we may be able to help you pursue compensation to pay for your medical bills.

Contact Us Now

Wegovy and NAION Risks

Semaglutide medications like Wegovy may increase the risk of NAION. This condition occurs when blood flow to the optic nerve is suddenly cut off, depriving it of oxygen and causing rapid, often irreversible vision loss.

Find out more about the risk of NAION from Wegovy: 

  • Patients who are prescribed a semaglutide like Wegovy for weight loss are over 7 times more likely to develop NAION than patients taking other weight loss medications, according to JAMA Ophthalmology.
  • Of the overweight or obese patients in the study who were prescribed semaglutide, 6.7% developed NAION within 36 months.
  • In June 2025, the World Health Organization issued a global safety alert about the risk of NAION associated with semaglutide medicines like Wegovy.

These findings have prompted growing concern among regulatory bodies worldwide, with the European Medicines Agency adding NAION as a side effect of Wegovy. However, the U.S. Food & Drug Administration has not yet followed suit.

NAION Symptoms from Wegovy

NAION often comes on suddenly and without warning, with many patients first noticing vision loss immediately upon waking up.

NAION symptoms from Wegovy may include:

  • Dark or blurry spots in parts of your vision
  • Sudden, painless vision loss
  • A visual field defect, such as losing the upper or lower half of your vision
  • Swelling of the optic nerve, which may be detected during an eye exam

Because this condition can progress rapidly, seeking immediate medical attention after the onset of symptoms is important to potentially help protect remaining vision.

Who Can File a NAION Wegovy Lawsuit?

If you developed NAION or experienced sudden vision loss after taking Wegovy or another semaglutide medication, you may have grounds to file a lawsuit against the drug’s manufacturer for failing to adequately warn you about this risk.

You may be able to file a lawsuit against Wegovy if you or a loved one:

  • Used a GLP-1 medication like Wegovy, Ozempic, Mounjaro, Rybelsus, Saxenda, Trulicity, or Zepbound
  • Suffered a serious health complication linked to the drug, like vision loss from NAION
  • Was hospitalized, went to the ER, or needed a follow-up with a specialist for your injury

You only have a limited amount of time to file a Wegovy NAION lawsuit due to state laws known as statutes of limitations. Once this deadline passes, you won’t be able to take legal action for your injuries again.

It’s important to contact our team as soon as possible, so you don’t miss your chance to pursue justice following your injury. Call (800) 995-1212 now.

How to File Wegovy Lawsuits for NAION

At Sokolove Law, we strive to make filing a lawsuit as stress-free as possible. Our Wegovy attorneys can handle every step of the legal process for you, so you can focus on your health during this difficult time.

Steps to filing a Wegovy lawsuit for NAION generally include:

  • Contacting Sokolove Law: We can determine your eligibility to take legal action during a free case review.
  • Gathering Evidence: Our team will collect medical records, testimony, and other evidence needed to build a strong case on your behalf.
  • Filing Your Wegovy Lawsuit: Your legal team will complete all necessary paperwork and file your claim within any state deadlines.
  • Negotiating a Wegovy Settlement: We’ll work to negotiate a Wegovy lawsuit settlement with the defendant(s).
  • Pursuing a Verdict in Court: If a Wegovy settlement is unable to be reached, your attorney will be prepared to present your case in court before a judge and jury.

Don’t suffer because someone else was careless. Call (800) 995-1212 now to begin your journey toward justice.

What to Look for in a Wegovy Lawyer

At Sokolove Law, our Wegovy attorneys have the resources and skills needed to level the playing field between victims and the drug manufacturers responsible for their injuries.

Learn how Sokolove Law stands out from other law firms:

  • Decades of Experience: For over 45 years, Sokolove Law has fought for compensation and justice on behalf of injured clients.
  • Track Record of Success: We’ve secured over $10.5 Billion total for our clients, including more than $1.6 Billion from claims involving dangerous drugs and medical devices.
  • Help Available in All 50 States: Regardless of where you’re located in the U.S., Sokolove Law may be able to help. Our firm has offices and attorneys nationwide.
  • No Financial Risks: Our Wegovy lawyers don’t charge any upfront or hourly fees, and we only get paid if your case results in compensation.

Let us put our experience to work for you. Reach out to our team now to get started.

See If Our Wegovy Lawyers Can Help

During a free case review, we can let you know if you may be eligible for compensation from a Wegovy lawsuit.

Get a Free Case Review

Get Help Filing an Ozempic Wegovy Lawsuit

If you or a loved one suffered serious complications after taking semaglutide medications like Wegovy or Ozempic, our dedicated attorneys are prepared to fight for justice on your behalf.

As a national law firm, Sokolove Law can help Wegovy users across the country pursue compensation for their injuries.

We’ve already secured over $1.6 Billion for clients harmed by dangerous drugs or medical devices.

Find out how a Wegovy lawyer may be able to help you. Call (800) 995-1212 now or fill out our contact form for a free, no-obligation case review.

Note: Do not change medications without first consulting your doctor.

All brands are trademarks of their respective companies.

NAION Wegovy Lawsuit Settlement FAQs

Is there a lawsuit against Ozempic and Wegovy?

Yes. Lawsuits have been filed against Novo Nordisk, the maker of Rybelsus, Ozempic, and Wegovy, alleging the company failed to properly warn users about the risks of these medications.

In one case, an Illinois man filed a Wegovy lawsuit after he took the drug for approximately 1 year before developing NAION, which caused serious and permanent vision loss. He is seeking compensation for loss of enjoyment of life, medical bills, lost income, and more.

Contact us now to see if you may be able to take legal action for NAION from Wegovy.

What are the Wegovy lawsuits about?

Lawsuits against Wegovy allege the drug’s manufacturer did not properly warn patients about risks associated with Wegovy, including the possibility of vision loss from NAION and stomach problems like gastroparesis.

Wegovy lawsuits involve claims of: 

  • Breach of warranty: Victims claim Novo Nordisk made representations about Wegovy's safety that proved false or misleading
  • Failure to warn: Novo Nordisk allegedly knew or should have known about the risk of NAION but failed to disclose it on Wegovy's label or in patient communications
  • Negligence: The company reportedly failed to conduct adequate safety monitoring and disclose emerging risks to patients and prescribers
  • Strict product liability: Wegovy is alleged to be an unreasonably dangerous product due to its undisclosed risks

Call (800) 995-1212 now to see if you may be eligible for the Wegovy lawsuit. It costs nothing to speak with us.

Is there a Wegovy class action lawsuit?

Wegovy lawsuits have been consolidated into 2 separate multidistrict litigation (MDL) proceedings, which are similar to a Wegovy class action lawsuit.

The Wegovy MDLs include: 

  • MDL No. 3163: There are currently 200 lawsuits pending in a NAION MDL, including claims involving Wegovy.
  • MDL No. 3094: At least 3,928 lawsuits have been filed by patients who took a GLP-1 medication and developed gastrointestinal issues.

Get a free legal consultation now to see if you may be able to pursue compensation from a Wegovy lawsuit.

Does Wegovy cause NAION?

Yes, potentially. Researchers have found that patients taking semaglutide medications like Wegovy for weight loss are over 7 times more likely to develop non-arteritic anterior ischemic optic neuropathy (NAION) than those taking other weight loss medications.

This may happen because semaglutide can cause rapid changes in blood sugar and circulation that impair blood flow to the optic nerve, according to a case report published in Clinical Practice and Surgical Cases.

Have Ozempic and Wegovy NAION lawsuits been centralized in 2026​?

Yes. At least 200 NAION lawsuits have been filed against GLP-1 companies and consolidated in a multidistrict litigation (MDL No. 3163).

Centralized in the Eastern District of Pennsylvania, the NAION MDL encompasses claims involving Novo Nordisk's Ozempic, Wegovy, Saxenda, and Rybelsus, as well as Eli Lilly's Mounjaro, Zepbound, and Trulicity.

How much does a Wegovy lawyer cost?

At Sokolove Law, there are no upfront or hourly fees to file a Wegovy lawsuit.

Our team only gets paid if your case successfully results in compensation, so there's no financial risk to taking legal action.

Who makes Wegovy?

The maker of Wegovy is Novo Nordisk, a Danish pharmaceutical company.

Is Ozempic and Wegovy the same drug?

No. Ozempic is approved to treat type 2 diabetes and is not meant to be used as a weight loss drug, while Wegovy is.

Both Ozempic and Wegovy contain semaglutide, which has been linked to serious physical and psychological side effects in some patients.

However, Wegovy often contains double the amount of semaglutide found in Ozempic, potentially increasing these risks.

What are common Wegovy side effects?

Patients can only make informed decisions about their health when they’re properly informed of the potential risks linked to their medications. Unfortunately, many patients feel they weren’t properly warned about certain side effects of Wegovy.

Serious side effects of Wegovy can include:

  • Vision loss caused by non-arteritic anterior ischemic optic neuropathy (NAION)
  • Stomach paralysis (gastroparesis)
  • Bowel or intestinal obstructions
  • Chronic vomiting
  • Deep vein thrombosis (DVT)
  • Esophageal injury
  • Ileus (intestinal inability to contract and pass waste)
  • Intraoperative pulmonary aspiration
  • Malnutrition-related disorders
  • Pancreatic cancer

If you suffered serious side effects after using Wegovy, contact Sokolove Law to learn more about your potential legal options.

  1. American Academy of Ophthalmology. "American Academy of Ophthalmology and North American Neuro-Ophthalmology Society Issue Advice on Weight Loss Drug and Eye Health." Retrieved from: https://www.aao.org/newsroom/news-releases/detail/weight-loss-drug-and-eye-health.
  2. Clinical Practice and Surgical Cases. “Is Semaglutide Linked to NAION? A Case Report on a Rare Ocular Complication.” Retrieved from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12372079/.
  3. CNN. “Woman sues drug makers of Ozempic and Mounjaro over severe gastrointestinal issues.” Retrieved from: https://www.cnn.com/2023/08/03/business/ozempic-mounjoro-lawsuit/index.html.
  4. European Medicines Agency. "PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy." Retrieved from: https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy.
  5. JAMA Network. “Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.” Retrieved from: https://jamanetwork.com/journals/jama/fullarticle/2810542.
  6. JAMA Ophthalmology. “Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.” Retrieved from: https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2820255.
  7. Medical News Today. “Ozempic vs. Wegovy.” Retrieved from: https://www.medicalnewstoday.com/articles/drugs-ozempic-vs-wegovy#takeaway.
  8. PHILADELPHIA COUNTY COURT OF COMMON PLEAS. “Kelly Miller vs. Novo Nordisk.” Retrieved from: https://fjdefile.phila.gov/efsfjd/zk_fjd_public_qry_00.zp_add_to_cart?uid=MhjHIrvGAIolqsSYDxam&o=VmpS_1o9WxozKg8&c=230901944&d=3&b=1&tfn=lZ8!PbJ6K.pdf.
  9. Reuters. “Wegovy class has higher GI side effect risk than older weight loss drug in study.” Retrieved from: https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-class-has-higher-gi-side-effect-risk-than-older-weight-loss-drug-study-2023-10-05/.
  10. U.S. Food and Drug Administration. “HIGHLIGHTS OF PRESCRIBING INFORMATION.” Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215256s005lbl.pdf.
  11. U.S. Food and Drug Administration. “Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss.” Retrieved from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss.
  12. World Health Organization. "The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION)." Retrieved from: https://www.who.int/news/item/27-06-2025-27-06-2025-semaglutide-medicines-naion.